Inventor · disambiguated record
Yoshiteru Eikyu
Also filed as: EIKYU YOSHITERU
8 granted patents·5 pending applications·54 citations·filing 1996–2008
84Inventor score
Top patents by PatentIndex Score
13 records- 0190US7465731B2HDAC inhibitorASTELLAS PHARMA INC·Filed 2005·Granted Dec 16, 2008·18 cites·18 claims
- 0285US7557127B2HDAC inhibitorASTELLAS PHARMA INC·Filed 2008·Granted Jul 7, 2009·8 cites·21 claims
- 0383US6787543B2Benzhydryl derivativesFUJISAWA PHARMACEUTICAL CO·Filed 2001·Granted Sep 7, 2004·22 cites·7 claims
- 0467US6924278B2Aroyl-piperazine derivatives, their preparation and their use as tachykinin antagonistsFUJISAWA PHARMACEUTICAL CO·Filed 2003·Granted Aug 2, 2005·3 cites·7 claims
- 0562US7166598B2Piperazine derivativesASTELLAS PHARMA INC·Filed 2004·Granted Jan 23, 2007·1 cites·15 claims
- 0652US2007123532A1Piperazine derivativesFUJISAWA PHARMACEUTICAL CO·Filed 2006·Application pending·0 cites
- 0747US2010069388A1N-hydroxyacrylamide compoundsASTELLAS PHARMA INC·Filed 2007·Application pending·0 cites
- 0845US5958914ACephem compoundsFUJISAWA PHARMACEUTICAL CO·Filed 1996·Granted Sep 28, 1999·2 cites·5 claims
- 0941US2005171350A1Benzhydryl derivativesFUJISAWA PHARMACEUTICAL CO·Filed 2002·Application pending·0 cites
- 1040US7750155B2Pyrazinyl hydroxyacrylamide compounds having an inhibitory effect on the activity of histone deacetylaseASTELLAS PHARMA INC·Filed 2007·Granted Jul 6, 2010·0 cites·30 claims
- 1139US2004220403A11-(2-Methoxybenzyl)-3-benzhydrylpiperazines as tachykinin anatgonistsFiled 2001·Application pending·0 cites
- 1232US6159961ACephem compoundsFUJISAWA PHARMACEUTICAL CO·Filed 1999·Granted Dec 12, 2000·0 cites·5 claims
- 1328US2003114668A1Aroyl-piperazine derivatives, their preparation and their use as tachykinin antagonistsFiled 1998·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Yoshiteru Eikyu files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →